Patient-reported outcomes are important in assessing the impact of new diabetes therapies on patient perceptions of quality of life (QoL). The QoL of patients using the Medtronic MiniMed™ 670G HCL system with SmartGuard™ technology, released for commercial use in March 2017, was examined. MiniMed™ 670G HCL system users (n=198) completed the validated Diabetes-39 (D-39) questionnaire prior to starting HCL system therapy and at 3-4 months post start. QoL was evaluated on a 7-point scale (1=Not Affected at All to 7=Extremely Affected) across 5 categories: energy and mobility, diabetes control, anxiety and worry, social burden, and sexual functioning. Paired t-test was used to compare the mean score for each attribute, and a two-tailed t-test determined statistical significance from baseline to 3-4 months after MiniMed™ 670G system use. All patients had responses indicating a positive experience after use of the system in Auto Mode. For all 5 categories, 160/198 patients (81%) experienced an outcome in the positive direction. The Table shows the top 10 criteria in which statistically significant improvement was observed. In addition to the previously reported improvements in glycemic control,1 these findings suggest that the MiniMed™ 670G system improves multiple domains in self-reported QoL measures, and particularly those concerning adherence to diabetes management.
S. Gopalakrishnan: Employee; Self; Medtronic. C. Fogel: Employee; Self; Medtronic. J. Mueckler: Employee; Self; Medtronic MiniMed, Inc..